ConductScience.org, home

Paper30836166

Dose Escalation for Prostate Adenocarcinoma: A Long-Term Update on the Outcomes of a Phase 3, Single Institution Randomized Clinical Trial.

Pasalic D and 13 others. Int J Radiat Oncol Biol Phys, 2019. Cited by 83 papers, by iCite.

Cite this record

ConductScience Library. Dose Escalation for Prostate Adenocarcinoma: A Long-Term Update on the Outcomes of a Phase 3, Single Institution Randomized Clinical Trial. Papers, record 30836166. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/30836166

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Dose Escalation for Prostate Adenocarcinoma: A Long-Term Update on the Outcomes of a Phase 3, Single Institution Randomized Clinical Trial.
PubMed
Journal
Int J Radiat Oncol Biol Phys
PubMed
Year
2019
PubMed
Publication types
Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.
PubMed
Citations, by iCite
83
iCite
Relative citation ratio, by iCite
3.86
iCite
Revised in PubMed
2021-11-22
PubMed

Authors14

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Pasalic DDario
2Kuban DADeborah A
3Allen PKPamela K
4Tang CChad
5Mesko SMShane M
6Grant SRStephen R
7Augustyn AAAlexander A
8Frank SJSteven J
9Choi SSeungtaek
10Hoffman KEKaren E
11Nguyen QNQuynh-Nhu
12McGuire SESean E
13Pollack AAlan
14Anscher MSMitchell S

Source PubMed

Download CSV of authors

Topics17

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
AdenocarcinomaMajor topic
Dose Fractionation, RadiationMajor topic
Prostatic NeoplasmsMajor topic
Salvage TherapyMajor topic
Aged
Aged, 80 and over
Follow-Up Studies
Humans
Kallikreins
Male
Middle Aged
Neoplasm Grading
Neoplasms, Second Primary
Prostate-Specific Antigen
Time Factors
Treatment Failure
Treatment Outcome

Source PubMed

Download CSV of topics

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
P01 CA006294NCI NIH HHSUnited StatesP01CA006294PubMed and NIHNIH RePORTER
P30 CA016672NCI NIH HHSUnited StatesP30CA016672PubMed and NIHNIH RePORTER

Download CSV of grants

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in31204661Long-Term Benefits of Dose-Escalation in Localized Prostate Cancer.https://conductscience.org/library/papers/31204661

Source PubMed

Download CSV of comments and corrections

References27

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
12114751470 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial.Int J Radiat Oncol Biol Phys2011https://conductscience.org/library/papers/21147514PubMed
28119066Sample size requirements and length of study for testing interaction in a 2 x k factorial design when time-to-failure is the outcome [corrected].Control Clin Trials1993https://conductscience.org/library/papers/8119066PubMed
324485765Second primary cancers after radiation for prostate cancer: a systematic review of the clinical data and impact of treatment technique.Radiother Oncol2014https://conductscience.org/library/papers/24485765PubMed
424725694Increasing use of dose-escalated external beam radiation therapy for men with nonmetastatic prostate cancer.Int J Radiat Oncol Biol Phys2014https://conductscience.org/library/papers/24725694PubMed
524581940Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial.Lancet Oncol2014https://conductscience.org/library/papers/24581940PubMed
618926640A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma.Cancer Treat Rev2009https://conductscience.org/library/papers/18926640PubMed
72762613610-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer.N Engl J Med2016https://conductscience.org/library/papers/27626136PubMed
824373762A Phase II study of salvage high-dose-rate brachytherapy for the treatment of locally recurrent prostate cancer after definitive external beam radiotherapy.Brachytherapy2014https://conductscience.org/library/papers/24373762PubMed
922318190[Quality of life after biochemical recurrence in patients with prostate cancer. How and how long do patients live after biochemical recurrence?].Arch Esp Urol2012https://conductscience.org/library/papers/22318190PubMed
109169810Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel.Int J Radiat Oncol Biol Phys1997https://conductscience.org/library/papers/9169810PubMed
1129904742Factors influencing prostate cancer patterns of care: An analysis of treatment variation using the SEER database.Adv Radiat Oncol2018https://conductscience.org/library/papers/29904742PubMed
1215990025The calculated risk of fatal secondary malignancies from intensity-modulated radiation therapy.Int J Radiat Oncol Biol Phys2005https://conductscience.org/library/papers/15990025PubMed
1329543933Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer: The NRG Oncology RTOG 0126 Randomized Clinical Trial.JAMA Oncol2018https://conductscience.org/library/papers/29543933PubMed
1422889401
Secondary cancers after intensity-modulated radiotherapy, brachytherapy and radical prostatectomy for the treatment of prostate cancer: incidence and cause-specific survival outcomes according to the initial treatment intervention.
BJU Int2012https://conductscience.org/library/papers/22889401PubMed
1511099319Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer.J Clin Oncol2000https://conductscience.org/library/papers/11099319PubMed
1616798415Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference.Int J Radiat Oncol Biol Phys2006https://conductscience.org/library/papers/16798415PubMed
1710974469External beam radiotherapy dose response characteristics of 1127 men with prostate cancer treated in the PSA era.Int J Radiat Oncol Biol Phys2000https://conductscience.org/library/papers/10974469PubMed
1820124169
Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09.
J Clin Oncol2010https://conductscience.org/library/papers/20124169PubMed
1912504054How low is the alpha/beta ratio for prostate cancer?Int J Radiat Oncol Biol Phys2003https://conductscience.org/library/papers/12504054PubMed
2025139441Radiation-induced secondary malignancy in prostate cancer: a systematic review and meta-analysis.Urol Int2014https://conductscience.org/library/papers/25139441PubMed

See all 27 referencesDownload CSV of references

Cited by54

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 83 citations.

PMIDTitleJournalYearIn PapersSource
42878878EQUIPOISE: EQUivalence In Prostate cancer treatment: surgery Or radiotherapy? An Intention-to-treat Survival analysis from real-world Evidence.World J Urol2026https://conductscience.org/library/papers/42878878PubMed
42728103Dosimetry-Driven Personalization of Radiopharmaceutical Therapies: Evidence and Opportunities.J Nucl Med2026https://conductscience.org/library/papers/42728103PubMed
42232852Polish Brachytherapy Society clinical recommendations and expert consensus on radical high-dose-rate brachytherapy for prostate cancer.J Contemp Brachytherapy2026https://conductscience.org/library/papers/42232852PubMed
42205730
Trial protocol: RadTARGET, a multicenter phase II randomized controlled trial evaluating focal radiotherapy boost with de-intensification of dose to non-suspicious prostate in patients with intermediate- or high-risk prostate cancer.
Clin Transl Radiat Oncol2026https://conductscience.org/library/papers/42205730PubMed
42028292Particle Therapy Co-Operative Group Consensus Statement on Reirradiation With Proton Therapy for Prostate Cancer.Int J Part Ther2026https://conductscience.org/library/papers/42028292PubMed
41809561Magnetic Resonance Imaging-Directed Stereotactic Body Radiation Therapy Microboost in Concert With Pelvic Nodal Irradiation for Prostate Cancer in the Higher-Risk Spectrum: Toxicity.Adv Radiat Oncol2026https://conductscience.org/library/papers/41809561PubMed
41634712Revisiting fractionation in prostate carbon ion therapy: first comparative analysis of biologically effective dose using mMKM with diverse parameters.Radiat Oncol2026https://conductscience.org/library/papers/41634712PubMed
41590513Treatment-Free Survival and the Pattern of Follow-Up Treatments After Curative Prostate Cancer Treatment, a Real-World Analysis of Big Data from Electronic Health Records from a Tertiary Center.J Pers Med2026https://conductscience.org/library/papers/41590513PubMed
41583333Natural History and Risk Stratification of Biochemically Recurrent Prostate Cancer Following Definitive Radiation Therapy.Adv Radiat Oncol2026https://conductscience.org/library/papers/41583333PubMed
41541754Dosimetric Feasibility of Dose-Painting Radiation Therapy for Targeting Hypoxia in Prostate Cancer on a Novel Ring Gantry Radiation Therapy System.Adv Radiat Oncol2026https://conductscience.org/library/papers/41541754PubMed
40564029Long-Term Outcomes After High-Dose-Rate Brachytherapy and Hypofractionated External Beam Radiotherapy in Very High-Risk Prostate Cancer: A 24-Year Follow-Up.Biomedicines2025https://conductscience.org/library/papers/40564029PubMed
40558303Dosimetric Comparison of VMAT Alone and VMAT with HDR Brachytherapy Boost Using Clinical and Biological Dose Models in Localized Prostate Cancer.Curr Oncol2025https://conductscience.org/library/papers/40558303PubMed
40558264Can Deep Learning-Based Auto-Contouring Software Achieve Accurate Pelvic Volume Delineation in Volumetric Image-Guided Radiotherapy for Prostate Cancer? A Preliminary Multicentric Analysis.Curr Oncol2025https://conductscience.org/library/papers/40558264PubMed
40518535Risk-adapted intensification therapy in high-risk prostate cancer: how relevant is the role of radiation dose.Radiat Oncol2025https://conductscience.org/library/papers/40518535PubMed
39901943Fully automatic reconstruction of prostate high-dose-rate brachytherapy interstitial needles using two-phase deep learning-based segmentation and object tracking algorithms.Clin Transl Radiat Oncol2025https://conductscience.org/library/papers/39901943PubMed
39855400The Determinants of Toxicity in the Treatment of Prostate Cancer With a Focal, Intraprostatic "Microboost".Int J Radiat Oncol Biol Phys2025https://conductscience.org/library/papers/39855400PubMed
39849412Hypofractionated image-guided radiotherapy with 70 Gy in 28 fractions for prostate cancer confined to the pelvis: a single institute experience in Taiwan.BMC Urol2025https://conductscience.org/library/papers/39849412PubMed
39802319The clinical application of in vivo dosimetry for gynaecological brachytherapy: A scoping review.Tech Innov Patient Support Radiat Oncol2025https://conductscience.org/library/papers/39802319PubMed
39628817Impact of androgen deprivation therapy in patients with unfavorable intermediate-risk prostate cancer receiving brachytherapy-based dose-escalated radiation therapy.J Contemp Brachytherapy2024https://conductscience.org/library/papers/39628817PubMed
39165591Dosimetric evaluation of ultrafractionated dose escalation with simultaneous integrated boost to intraprostatic lesion using 1.5-Tesla MR-Linac in localized prostate cancer.Rep Pract Oncol Radiother2024https://conductscience.org/library/papers/39165591PubMed

See all 54 cited byDownload CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
KLK3354PubTator's text mininghttps://conductscience.org/library/genes/354

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/30836166

GET https://conductscience.org/api/papers/v1/30836166/references?page=2